The biotech's misstep in Alzheimer's disease proved costly for shareholders last month.
Which of these two pioneering cannabis plays is the better buy right now?
These two biotechs have been stellar growth vehicles for investors, but only one stock is worth buying right now.
Shares of Gilead Sciences and Teva Pharmaceutical Industries are bargains right now.
The market wasn't kind to this Canadian pot stock last week, but a rebound could be imminent.
Genfit, Changyou, and Children's Place aren't turning heads on Wall Street quite yet, but that could change very soon.
Wall Street has turned sour on Cronos' near-term outlook. Should everyday investors do the same?
Eli Lilly and GlaxoSmithKline are both pharma royalty. Which stock is the better buy right now?
BioMarin, Waste Management, and Walmart are three top defensive picks worth buying now.
Catalyst Pharmaceuticals and HEXO could both be on the verge of a long-tailed growth trend.
AbbVie and Eli Lilly are two rock-solid dividend plays, but only one is a buy right now.
Biogen's closely-watched Alzheimer's drug fails to move in the needle in two late-stage trials.
Tilray should consider a merger or possibly risk losing its premium valuation.
Novavax needs a deep-pocketed partner soon.
The drugmaker's Q4 earnings release was a big hit with investors.
The first stock you ever buy could be the most important. These three names won't disappoint.
BioScrip's fourth-quarter results and merger with Option Care Enterprises aren't sitting well with shareholders.
These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.
Investors are cheering HEXO's recent acquisition and strong second-quarter results today.
Aurora is hoping to attract a big-time partner to fund its global expansion.